Try our beta test site
284 studies found for:    GVHD AND chronic
Show Display Options
Rank Status Study
1 Active, not recruiting Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Condition: Chronic GVHD
Interventions: Drug: Sirolimus + calcineurin inhibitor + prednisone;   Drug: Sirolimus + prednisone
2 Unknown  Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Condition: Steroid-Refractory Chronic GVHD
Intervention: Drug: Rituximab
3 Completed Alefacept for Chronic Graft Versus Host Disease
Condition: Resistant Chronic GVHD
Intervention: Drug: Alefacept
4 Completed
Has Results
Campath in Chronic GVHD
Condition: Chronic Graft-vs.-Host Disease
Intervention: Drug: Alemtuzumab (Campath)
5 Recruiting Multiple Donor Treg DLI for Severe Refractory Chronic GVHD
Condition: Chronic Graft Versus Host Disease
Intervention: Biological: T reg DLI
6 Recruiting Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD
Condition: Chronic GVHD After HCT for Cancer or Immune Disease
Intervention: Other: Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.
7 Terminated Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)
Condition: Chronic Graft Versus Host Disease
Intervention: Other: PET-CT Scan
8 Active, not recruiting Improving Outcomes Assessment in Chronic GVHD
Condition: Chronic Graft Versus Host Disease
Intervention:
9 Completed
Has Results
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Rituximab
10 Active, not recruiting Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD
Condition: Chronic Graft Versus Host Disease
Intervention: Drug: Ponesimod
11 Recruiting A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Graft-versus-host-disease
Interventions: Procedure: Extracorporeal Photopheresis (ECP);   Drug: Interleukin-2
12 Unknown  Treatment of Chronic GVHD of Liver or Lungs by ECP
Condition: Chronic Graft-Versus Host Disease
Intervention: Procedure: Extracorporeal photoimmunotherapy
13 Recruiting Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells
Condition: Chronic Graft-Versus-Host Disease
Intervention: Biological: Mesenchymal Stromal Cells
14 Terminated Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)
Condition: Chronic Gastrointestinal Graft vs Host Disease
Interventions: Drug: orBec;   Drug: Placebo
15 Recruiting Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Conditions: Chronic Graft Versus Host Disease;   Chronic GVHD;   Complications of Organ Transplant Stem Cells
Interventions: Other: Treg-enriched infusion;   Drug: Interleukin-2
16 Withdrawn A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
Condition: Chronic Graft-Versus-Host Disease
Interventions: Drug: LBH589;   Drug: Methylprednisolone
17 Unknown  Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease
Condition: Chronic Graft-versus-host Disease
Interventions: Biological: Mesenchymal stem cells;   Biological: Non-mesenchymal stem cells
18 Active, not recruiting Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Bortezomib
19 Terminated UVB Phototherapy Treatment of Oral Chronic GVHD
Condition: Oral Chronic Graft-Versus-Host Disease
Intervention: Procedure: Narrow-Band UVB Phototherapy
20 Recruiting Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
Condition: Chronic Graft Versus Host Disease
Intervention: Drug: Ofatumumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.